Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

206.00
-0.2350-0.11%
Volume:3.71M
Turnover:765.26M
Market Cap:364.07B
PE:87.29
High:207.78
Open:206.72
Low:204.28
Close:206.23
52wk High:244.81
52wk Low:164.39
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.91
T/O Rate:0.21%
Dividend:6.65
Dividend Rate:3.23%
EPS(TTM):2.36
EPS(LYR):2.36
ROE:6225.00%
ROA:9.81%
PB:-111.34
PE(LYR):87.29

Loading ...

Abbvie Exec Says Co Anticipates Total Sales Growth of 9.5% in 2026

THOMSON REUTERS
·
Feb 04

Abbvie Exec Says Co Is Well Positioned to Deliver High Single Digit Revenue Growth Through 2029- Conf Call

THOMSON REUTERS
·
Feb 04

Abbvie Expects 2026 Aesthetics Sales of $5 Billion Including Botox Cosmetic Revenue of $2.7 Billion

THOMSON REUTERS
·
Feb 04

Abbvie Exec Says Expect 2026 Skyrizi Revenue of $21.5 Billion Driven and Rinvoq Revenue of $10.1 Billion

THOMSON REUTERS
·
Feb 04

Abbvie Expects First-Quarter Adjusted Earnings per Share Between $2.97 and $3.01

THOMSON REUTERS
·
Feb 04

Abbvie Exec Says Anticipate Aesthetics Growth Will Remain Challenged in 2026 and Focused on Investing to Stimulate the Market, Which Remains Highly Under Penetrated

THOMSON REUTERS
·
Feb 04

AbbVie's Q4 Earnings Beat Expectations as Botox Drives Rare Growth in Aesthetics Unit, Firm Raises Full-Year Profit Outlook

Stock News
·
Feb 04

AbbVie veröffentlicht Präsentation zum aktuellen Forschungs- und Entwicklungsstand der Pipeline

Reuters
·
Feb 04

AbbVie Q4 revenue beats expectations on immunology growth

Reuters
·
Feb 04

AbbVie reports Q4 net revenues of USD 16.62 billion, up 10 percent

Reuters
·
Feb 04

Abbvie Shares up 1% Premarket After Forecasting 2026 Profit Above Estimates

THOMSON REUTERS
·
Feb 04

GUIDANCE: (ABBV) AbbVie Expects 2026 Adjusted EPS Range $14.37 to $14.57, vs. FactSet Est of $14.27

MT Newswires Live
·
Feb 04

Earnings Flash (ABBV) AbbVie Posts Q4 Adjusted EPS $2.71, vs. FactSet Est of $2.65

MT Newswires Live
·
Feb 04

AbbVie Q4 Adj. EPS $2.71 Beats $2.65 Estimate, Sales $16.618B Beat $16.421B Estimate

Benzinga
·
Feb 04

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

Reuters
·
Feb 04

BRIEF-Abbvie Q4 Adjusted EPS USD 2.71 Vs. IBES Estimate USD 2.65

Reuters
·
Feb 04

Abbvie Q4 Adj EPS $2.71 VS Ibes Estimate $2.65

THOMSON REUTERS
·
Feb 04

Abbvie Q4 Results Include Unfavorable Impact of $0.71 per Share Related to Acquired Ipr&D and Milestones Expense

THOMSON REUTERS
·
Feb 04

Abbvie: Expect Another Year of Robust Growth in 2026

THOMSON REUTERS
·
Feb 04

Abbvie Outlook 2026 Adj EPS $14.37 - $14.57 VS Ibes Estimate $14.24

THOMSON REUTERS
·
Feb 04